Abnormal Liver Function Tests in Patients with Type 1 Diabetes Mellitus: Prevalence, Clinical Correlations and Underlying Pathologies
Overview
Affiliations
Aims: To determine the prevalence of elevated alanine transaminase (ALT) in a large cohort of patients with Type 1 diabetes and to examine the clinical correlations and causes. Methods Patients with Type 1 diabetes mellitus were prospectively recruited and ALT, glycated haemoglobin and lipid profile were measured. Patients with Type 2 diabetes mellitus were recruited as a comparison group.
Patients: with abnormal ALT were investigated for underlying causes. Prevalence of abnormal ALT was analysed at three separate cut-offs and multivariable analysis used to identify independent risk factors.
Results: Nine hundred and eleven with Type 1 diabetes and 963 with Type 2 diabetes were included. The prevalence of elevated ALT was dependent on the cut-off value: > 30 IU/l in males and > 19 IU/l in females, > 50 and > 63 IU/l was 34.5, 4.3 and 1.9%, respectively, in Type 1 diabetes and 51.4, 8.2 and 3.7%, respectively, in Type 2 diabetes. In Type 1 diabetes an elevated ALT was associated with worse glycaemic control, age > 55 years and elevated triglycerides. Investigation of these patients revealed a cause in 43.6% of patients, predominantly non-alcoholic fatty liver disease (NAFLD).
Conclusions: Elevated ALT is not uncommon in Type 1 diabetes and is associated with NAFLD-related risk factors. Patients with Type 1 diabetes and elevated ALT should be investigated as significant abnormalities may be found which are amenable to interventions.
Tomaszewska E, Dobrowolski P, Muszynski S, Donaldson J, Golynski M, Zwolska J J Clin Med. 2024; 13(18).
PMID: 39337082 PMC: 11433195. DOI: 10.3390/jcm13185595.
Group-informed attentive framework for enhanced diabetes mellitus progression prediction.
Sheng C, Wang L, Long C, Yue R Front Endocrinol (Lausanne). 2024; 15:1388103.
PMID: 38978615 PMC: 11228145. DOI: 10.3389/fendo.2024.1388103.
Heyns I, Arora M, Ganugula R, Allamreddy S, Tiwari S, Shah D ACS Nano. 2024; 18(18):11863-11875.
PMID: 38622996 PMC: 11145941. DOI: 10.1021/acsnano.4c01027.
Muzaffar H, Qamar I, Bashir M, Jabeen F, Irfan S, Anwar H Metabolites. 2023; 13(4).
PMID: 37110174 PMC: 10142569. DOI: 10.3390/metabo13040516.
Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology.
Memaj P, Jornayvaz F Front Endocrinol (Lausanne). 2022; 13:1031633.
PMID: 36531463 PMC: 9752856. DOI: 10.3389/fendo.2022.1031633.